HC Wainwright & Co. Reiterates Neutral on CymaBay Therapeutics, Maintains $32.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce reiterates a Neutral rating on CymaBay Therapeutics (NASDAQ:CBAY) and maintains a $32.5 price target.
February 29, 2024 | 2:07 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Ed Arce reiterates a Neutral rating on CymaBay Therapeutics and maintains a $32.5 price target.
The reiteration of a Neutral rating and maintenance of the price target suggests no significant short-term price movement is expected. The analyst's view likely reflects a balanced outlook on the company's prospects, indicating neither strong upside nor downside risk in the near term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 90